RxDoctor Payments Data

Cindy Chan, MD

Internal Medicine · Niskayuna, NYNPI 1407879026

Payments from drug & device makers

$1,533in general payments, 2019–2025

Across 81 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$187
  • Lilly USA, LLC$169
  • Novo Nordisk$152
  • AstraZeneca$148
  • Boehringer Ingelheim$136
  • GSK$127
  • plus $614 from 18 others

What the payments were for

  • Food & beverage$1,52199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,533 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$113,445
Medicare patients
216
Services billed
2,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$100,419
OzempicSemaglutide78$78,485
FarxigaDapagliflozin Propanediol43$54,595
TrulicityDulaglutide34$44,878
JanuviaSitagliptin Phosphate20$31,477
SynthroidLevothyroxine Sodium229$21,229
Breo ElliptaFluticasone/Vilanterol31$15,992
Nurtec OdtRimegepant Sulfate13$12,154
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,028
Ezetimibe156$7,924
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$6,344
Atorvastatin Calcium495$6,286
Duloxetine Hcl124$4,898
PremarinEstrogens, Conjugated18$4,854
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$152$78,48578 claims
AstraZenecaFarxiga$148$54,59543 claims
Lilly USA, LLCTrulicity$169$44,87834 claims
GSKBreo Ellipta, Trelegy Ellipta$127$25,02043 claims
AbbVieSynthroid$187$21,229229 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$38$4,440315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Niskayuna

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →